JPMorgan initiates Spyre stock with Overweight on IBD pipeline

JPMorgan has begun tracking Spyre Therapeutics Inc. (NASDAQ:SYRE) and assigned an Overweight rating with a $110.00 price target. The firm sees significant upside potential in Spyre's pipeline of six clinical-stage assets focused on inflammatory bowel disease. The company's three monotherapies targeting α4β7, TL1A, and IL-23 have reported Phase 2 data that analysts view as competitive.

Additionally, there are three combination programs with Phase 2 results expected in 2027. Spyre's combination therapies, according to JPMorgan, can differentiate the company from competitors through improved convenience and reduced dosing frequency. The firm projects Spyre could capture a low-teens percentage share of the U.S. advanced biologics IBD market by the 2040s, potentially generating $6 billion to $7 billion in annual worldwide sales.

While JPMorgan acknowledges Spyre's current lack of profitability typical for clinical-stage biotech firms, the firm remains optimistic about the company's potential to partner with large pharmaceutical entities for sustained growth in the coming decade.